Full-Time

Machine Learning Engineer

Posted on 7/8/2024

ArteraAI

ArteraAI

51-200 employees

Personalizes prostate cancer therapy using deep learning

Biotechnology
Healthcare

Compensation Overview

$140k - $200kAnnually

Mid

Remote in USA

Category
Deep Learning
Computer Vision
AI & Machine Learning
Required Skills
Pytorch
Computer Vision
Requirements
  • 3+ years of industry experience using PyTorch
  • 2+ years of experience as a technical lead
  • Experience launching and maintaining products in a production environment
  • Experience communicating technical (ML) details to a cross-functional team of non-technical collaborators.
Responsibilities
  • Leading the technical effort of developing novel biomarkers alongside fellow ML scientists, engineers, biostatisticians, and scientific directors
  • Design and develop innovative computer vision models that predict patient outcomes and responses to therapy
  • Aid in the productionalization, launch, and monitoring of machine learning products
  • Research and development of machine learning algorithms that expand product capabilities
  • Contribute to and drive publications in scientific journals and machine learning conferences
  • Help grow and mentor a team of machine learning scientists and engineers

Artera.ai focuses on personalizing therapy for prostate cancer through its main product, the ArteraAI Prostate Test, which is a clinical laboratory test developed in-house. This test utilizes advanced multi-modal deep learning techniques to analyze patient data and provide tailored treatment options. Unlike many competitors, Artera.ai's test is not experimental; it is used in actual clinical settings, ensuring reliability and effectiveness. The company serves healthcare providers, hospitals, and individual patients, generating revenue through the sale of their prostate test. Artera.ai aims to enhance the treatment of prostate cancer by offering a more personalized approach, backed by rigorous clinical trials and continuous improvement efforts.

Company Stage

Seed

Total Funding

$107M

Headquarters

Menlo Park, California

Founded

2021

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • ArteraAI secured $20 million funding for international expansion and growth.
  • Inclusion in NCCN Guidelines boosts ArteraAI's credibility and market acceptance.
  • Partnership with CorePlus enhances validation of ArteraAI Prostate Test.

What critics are saying

  • Increased competition from AI diagnostic companies may erode ArteraAI's market share.
  • Reliance on H&E histopathology images could be challenged by new diagnostic technologies.
  • Focus on prostate cancer may limit market potential if competitors diversify.

What makes ArteraAI unique

  • ArteraAI's platform uses multimodal AI for personalized prostate cancer therapy.
  • The ArteraAI Prostate Test is the first AI-enabled test in NCCN Guidelines.
  • ArteraAI collaborates with Movember to advance prostate cancer treatment.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE